FBXO35, also known as F-box only protein 35, is a member of the F-box protein family, which is characterized by an approximately 40-amino-acid F-box motif. This motif is crucial for the protein's role in the ubiquitin-proteasome pathway, where F-box proteins often function as specificity factors for the SCF (SKP1-cullin-F-box) E3 ubiquitin ligase complex.The primary function of FBXO35 is to mediate the ubiquitination of target proteins, marking them for degradation by the 26S proteasome. This process is vital for various cellular processes, including cell cycle regulation, signal transduction, and transcriptional control. By targeting specific substrates for degradation, FBXO35 plays a role in maintaining protein homeostasis and regulating the abundance of key regulatory proteins within the cell.
FBXO35 has been studied in the context of its interaction with particular substrates. For example, it has been implicated in the regulation of cell proliferation through its interaction with specific cell cycle regulators. By mediating the degradation of these proteins, FBXO35 can influence cell cycle progression and, consequently, impact processes like cell growth and differentiation.Like other F-box proteins, FBXO35 interacts with SKP1, cullin, and Rbx1 to form the SCF complex. Through its F-box domain, FBXO35 recruits specific substrates to the SCF complex, facilitating their ubiquitination by the attached E2 ubiquitin-conjugating enzyme. The specificity of FBXO35 for its substrates is determined by additional protein-protein interaction domains that recognize and bind to specific degradation signals (degrons) within the target proteins.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that could indirectly affect FBXO35 by altering protein degradation pathways. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Another proteasome inhibitor, potentially influencing FBXO35 activity by impacting ubiquitin-proteasome system. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A specific proteasome inhibitor, used to block proteasomal degradation, potentially affecting FBXO35 activity. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
An irreversible proteasome inhibitor, could impact FBXO35 by altering protein turnover. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A selective proteasome inhibitor, potentially influencing FBXO35 by modulating proteasomal activity. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
An oral proteasome inhibitor, potentially affecting FBXO35 by altering proteasomal degradation pathways. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
A proteasome inhibitor, could indirectly affect FBXO35 by modulating protein turnover in cells. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
A boronic acid-based proteasome inhibitor, potentially affecting FBXO35 activity through proteasomal inhibition. | ||||||
ONX 0914 | 960374-59-8 | sc-477437 | 5 mg | $245.00 | ||
An immunoproteasome inhibitor, potentially affecting FBXO35 through selective inhibition of proteasomal activity. | ||||||